PGY2 Oncology Pharmacy Resident UW Health- Madison Madison, Wisconsin, United States
Poster Abstract: Background It is well established in literature that pharmacists in oncology clinic settings provide valuable benefits to patient care including improvements in clinical outcomes, patient and provider education, and decreased healthcare costs. As oncology pharmacists’ roles expand in the clinic setting, it is pertinent to understand how current and future pharmacist resources should be justified and allocated.
Pharmacist productivity is a difficult metric to accurately and efficiently track, and yet is an important factor in departmental budgeting and FTE allocation. Productivity tracking tools are available to track pharmacist productivity, however, differ by institution and have primarily been implemented within inpatient settings.
In the Fall of 2024, University of Wisconsin (UW) Health will complete construction on the Eastpark Medical Center. This outpatient facility will include an expanded footprint for oncology care at UW Health, including increased capacity for oncology clinic care and additional pharmacist FTE.
Existing productivity metrics in the oncology clinic setting already exist at our institution and we are interested in improving efficiency and automation of those processes. This project will maximize resources by determining oncology clinic pharmacists’ priorities and utilize information technology to create a pharmacist clinic productivity tracking tool. These interventions will help better identify and document oncology clinic pharmacist functions. Completion of this project will be crucial to minimizing disruptions in patient care and facilitate easier adaptations in the current clinic model to address growth in our new and existing oncology clinic spaces.
Methods This quality improvement project will span across several sites within UW Health. A collection of clinic pharmacists will be assembled as part of the larger stakeholder team. a. Objective 1: Describe our current oncology clinic pharmacist model/key functions and compare practices to clinics at peer academic medical centers. i. The current UW oncology clinic model will be described via a SWOT analysis and swim lane diagram. ii. A group of clinic models at other academic medical centers will be assessed to compare to our current clinic model. b. Objective 2: Designate priority oncology pharmacist clinic functions i. Specific designation of oncology clinic pharmacist functions will be described. ii. Recommendations will be used in the creation of a productivity tracking tool. c. Objective 3: Create a tool within the EHR to accurately track oncology pharmacist productivity in the clinic setting. i. Productivity tracking tool will be built to track and measure aspects of pharmacist workflows that are deemed essential.
Results TBD
Discussion TBD
References (must also be included in final poster): 1. Patel MP, Barbour SY, Moorman MT. Value Assessment of Oncology Pharmacist Interventions. J Adv Pract Oncol. 2023;14(4):329-331. doi:10.6004/jadpro.2023.14.4.7 2. Virani A, Schlei Z, Gleason C, et al. Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic. Clin Lymphoma Myeloma Leuk. 2020;20(9):e543-e546. doi:10.1016/j.clml.2020.04.012 3. de Grégori J, Pistre P, Boutet M, et al. Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department. J Oncol Pharm Pract. 2020;26(5):1172-1179. doi:10.1177/1078155220915763 4. Meleis LA, Patel MP, DeCoske M, Moorman M, Bush PW, Barbour S. Evaluation of the Role and Impact of Ambulatory Clinical Pharmacists in an Academic Comprehensive Cancer Center. J Adv Pract Oncol. 2020;11(8):817-824. doi:10.6004/jadpro.2020.11.8.2 5. Clemmons AB, Alexander M, DeGregory K, Kennedy L. The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group. Biol Blood Marrow Transplant. 2018;24(5):914-922. doi:10.1016/j.bbmt.2017.12.803 6. Booth JP, Kennerly-Shah JM, Kelley LR, et al. Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network [published online ahead of print, 2023 Feb 19]. J Oncol Pharm Pract. 2023;10781552231157660. doi:10.1177/10781552231157660 7. Griffin SP, Signorelli JR, Lasko A, et al. Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey [published online ahead of print, 2023 May 16]. J Oncol Pharm Pract. 2023;10781552231174858. doi:10.1177/10781552231174858 8. Pawloski P, Cusick D, Amborn L. Development of clinical pharmacy productivity metrics. Am J Health Syst Pharm. 2012;69(1):49-54. doi:10.2146/ajhp110126 9. Lewis P. Right patient, right time, right pharmacist: the time for clinical prioritization tools?. Eur J Hosp Pharm. 2017;24(6):314. doi:10.1136/ejhpharm-2017-001395
